Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 15Terminated 6Recruiting 3Unknown 2Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Wilms Tumor 1Sarcoma, Kaposi 1Sarcoma 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Liposarcoma 1Hodgkin Disease 1Her2-negative Metastatic Breast Cancer 1Carcinoma, Ovarian Epithelial 1Acquired Immunodeficiency Syndrome 1AIDS-related Kaposi sarcoma 1

Interventions

Paclitaxel 2liposomal doxorubicin 1irinotecan sucrosofate 1fluzoparib 1envafolimab 1apatinib 1anlotinib 1Topotecan 1Surgical Procedures, Operative 1Neoadjuvant Therapy 1Losartan 1Indocyanine Green 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma, Ovarian Epithelial × liposomal doxorubicin × Clear all
NCT07545460 2026-04-22

A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Not yet recruiting
404 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡